Dilek MEMİŞ, MÜŞERREF OTKUN, Meral BAHAR, NECDET SÜT

Growth of Escherichia coli in atracurium, rocuronium, mivacurium, cisatracurium, pancuronium, and vecuronium

Amaç: Biz çalışmamızda atrakuryum, rokuronyum, mivakuryum, sisatrakuryum, pankuronyum ve vekuronyumun Escherichia coli üremesi üzerine olan etkinliğini araştırdık. Hastalar ve Yöntemler: Patojen bakteri, atrakuryum, rokuronyum, mivakuryum, sisatrakuryum, pankuronyum ve vekuronyum ile 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, ve 24 saat oda sıcaklığında temas ettirildi. Bulgular: Escherichia coli ortalama koloni sayısı rokuronyumda istatiksel anlamlı olarak atrakuryum, mivakuryum, sisatrakuryum, pankuronyum ve vekuronyumdan daha düşük saptandı (sırasıyla p=0.002, 0.000, 0.000, 0.001, ve 0.002). Atrakuryum, mivakuryum, sisatrakuryum, pankuronyum ve vekuronyumda ortalama koloni sayısı açısından anlamlı fark saptanmadı (p

Anahtar Kelimeler:

Pankuroniyum, Vekuronyum bromid, Escherichia coli, Atrakuriyum, Donanım kontaminasyonu

Atrakuryum, rokuronyum, mivakuryum, sisatrakuryum, pankuronyum ve vekuronyumda Escherichia coli üremesi

Objectives: We studied in vivo growth of Escherichia coli in atracurium, rocuronium, mivacurium, cisatracurium, pancuronium, and vecuronium. Patients and Methods: The pathogen was exposed to atracurium, rocuronium, mivacurium, cisatracurium, pancuronium and vecuronium for 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 h at room temperature, respectively. Results: The mean colony counts of Escherichia coli after exposure to rocuronium was significantly lower than the counts after exposure to atracurium, mivacurium, cisatracurium, pancuronium and vecuronium (p=0.002, 0.000, 0.000, 0.001, and 0.002, respectively). No significant difference was found with respect to the mean colony counts with atracurium, mivacurium, cisatracurium, pancuronium and vecuronium (p<0.05). Conclusion: Rocuronium had more powerful antimicrobial effects than the other neuromuscular agents.

Keywords:

Pancuronium, Vecuronium Bromide, Escherichia coli, Atracurium, Equipment Contamination,

PDF

___

1) Bátai I, Kerényi M, Tekeres M. The impact of drugs used in anaesthesia on bacteria. Eur J Anaesthesiol 1999;16:425-40.
2) Lessard MR, Trépanier CA, Gourdeau M, Denault PH. A microbiological study of the contamination of the syringes used in anaesthesia practice. Can J Anaesth 1988;35:567-9.
3) Morgan GE, Mikhail MS. Muscle relaxants. In: Clinical anesthesiology. 2nd ed. Stamford: Appleton & Lange; 1996. p. 149-64.
4) Graystone S, Wells MF, Farrell DJ. Do intensive care drug infusions support microbial growth? Anaesth Intensive Care 1997;25:640-2.
5) Sato S, Sakuragi T, Dan K. Human skin flora as a potential source of epidural abscess. Anesthesiology 1996;85:1276-82.
6) Sakuragi T, Yanagisawa K, Shirai Y, Dan K. Growth of Escherichia coli in propofol, lidocaine, and mixtures of propofol and lidocaine. Acta Anaesthesiol Scand 1999;43:476-9.
7) Pere P, Lindgren L, Vaara M. Poor antibacterial effect of ropivacaine: comparison with bupivacaine. Anesthesiology 1999;91:884-6.
8) Hodson M, Gajraj R, Scott NB. A comparison of the antibacterial activity of levobupivacaine vs. bupivacaine: an in vitro study with bacteria implicated in epidural infection. Anaesthesia 1999;54:699-702.
9) Aydin ON, Eyigor M, Aydin N. Antimicrobial activity of ropivacaine and other local anaesthetics. Eur J Anaesthesiol 2001;18:687-94.
10) Bátai I, Kerényi M, Falvai J, Szabó G. Bacterial growth in ropivacaine hydrochloride. Anesth Analg 2002;94:729-31.
11) Kampe S, Poetter C, Buzello S, Wenchel HM, Paul M, Kiencke P, et al. Ropivacaine 0.1% with sufentanil 1 μg/ml inhibits in vitro growth of pseudomonas aeruginosa and does not promote multiplication of staphylococcus aureus. Anesth Analg 2003;97:409-11.
12) Feldman JM, Chapin-Robertson K, Turner J. Do agents used for epidural analgesia have antimicrobial properties? Reg Anesth 1994;19:43-7.
13) Wierda JM, Kleef UW, Lambalk LM, Kloppenburg WD, Agoston S. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth 1991;38:430-5.
14) Atherton DP, Hunter JM. Clinical pharmacokinetics of the newer neuromuscular blocking drugs. Clin Pharmacokinet 1999;36:169-89.
15) Roy JJ, Varin F. Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship. Br J Anaesth 2004;93:241-8.
16) Wierda JM, Proost JH. Structure-pharmacodynamicpharmacokinetic relationships of steroidal neuromuscular blocking agents. Eur J Anaesthesiol Suppl 1995;11:45-54.
17) Wierda JMKH, Proost JH, Muir AW, Marshall RJ. Design of drugs for rapid onset. Anaesth Pharmacol Rev 1993;1:57-68.
18) Wu C, Engler C, Norton R. Growth of Staphylococcus epidermidis in anaesthetic resuscitative drugs: implications for potential contamination. Anaesth Intensive Care 2005;33:69-72.
19) Zacher AN, Zornow MH, Evans G. Drug contamination from opening glass ampules. Anesthesiology 1991;75:893-5.
20) MacPherson RD. Pharmaceutics for the anaesthetist. Anaesthesia 2001;56:965-79.